Mifepristone for the Treatment of Uterine Leiomyomas

Abstract

I.

Report on Repeated Mifepristone Treatment for Uterine Fibroids or Endometriosis

“…We can find no logical explanation for this result as there should not be any difference in the endometrial response to the action of mifepristone dependent on whether the subject suffers from uterine fibroids or endometriosis. In fact, for example, the increases in endometrial thickness in our previous studies into both conditions [4][5][6][7][8][9]25] and in both subgroups in the present study are similar. Anyway, given that the PAECs are considered to be "physiological" modifications of the endometrium, the only point of importance to be noted in this section is the non-existence of any case of endometrial hyperplasia or of any other pathology either in the post-treatment biopsies or, of course, in the pre-treatment biopsies regardless of whether it was the second, third or fourth treatment.…”

Medical Treatment of Fibroid to Decrease Rate of Hysterectomy

“…One potential link between the effects of the two key steroid hormones on ULMs is that estradiol induced the expression of the progesterone receptor and supported progesterone action on leiomyoma tissue [48]. Clinical findings also support these laboratory observations; studies have involved the evaluation of mifepristone (RU 486) [50][51][52], azoprisnil [43,49], and more recently, CDB-2914 and CDB-4124 (CDB: Contraceptive Development Branch) [53].…”

Contemporary management of uterine fibroids: focus on emerging medical treatments

“…Mifepristone is another SPRM that has been extensively researched but is not yet available in Canada for the treatment of UF. Various doses of mifepristone (2.5-50 mg) have been tested in the treatment of UFs, with reported reduction of UF size of up to 57% by 3 months of therapy 63,64 . As with ulipristal acetate, mifepristone therapy is associated with the development of PAEC 64,65 .…”